The In Vivo Pharmacology Department primarily provides clients with in vivo pharmacology services and services using in vivo materials. Its disease areas mainly cover oncology, metabolism, inflammation, central nervous system (CNS) diseases, etc. It has accumulated rich experience in the establishment of disease models, pharmacodynamic evaluation and screening, PD/PK and MOA experiments, etc. Collaborating with multiple departments such as Pharmacokinetics/Bioanalysis, In Vitro Pharmacology, and In Vitro Biology, it can provide comprehensive solutions for clients in different disease areas*.
In Vitro Detection
- Cell proliferation inhibition assay
- Chicken embryo angiogenesis inhibition assay
- In vitro antibacterial and antiviral detection
- Flow cytometry detection
- ELISPOT detection
- ELISA detection
- In vitro neutralization assay for TNF-α target drugs
- Cell activity and binding activity detection for PCSK9 target drugs
Animal Disease Models
Oncology Disease Models
- Human tumor cell line mouse models (subcutaneous xenografts, orthotopic xenografts (lung, liver, brain), systemic models)
- Human tumor cell line rat models
- Tumor immunology animal models (humanized, murine)
- In vivo tumor imaging models
- Patient-derived tumor xenograft (PDX) models
- Animal models of drug-resistant tumor strains
- Androgen-dependent/independent tumor models
- Animal models related to radiotherapy
- PTX (animals imported from Jackson Lab)
- Immune-reconstituted mouse tumor models
Hematological System Diseases
- Coagulation and bleeding disorders
- Granulocytopenia
- Thrombocytopenia
- Anemia
Cardiovascular and Cerebrovascular Diseases
- Atherosclerosis
- Myocardial infarction
- Cerebral embolism
Neuropsychiatric Diseases
- Drug addiction
- Drug withdrawal
- Mouse dementia models
Respiratory Diseases
- Pulmonary fibrosis
- Pulmonary embolism
- Asthma
Metabolic System Diseases
- Diabetes mellitus
- Insulin resistance
- Obesity
- Hyperlipidemia (for PCSK9 target drugs)
- Hyperuricemia
Urinary System Diseases
- Drug-induced kidney injury
- Surgery-induced kidney injury
- Renal insufficiency, etc.
Immune and Non-immune Inflammatory Disease Models
- Arthritis models
- Acute and chronic pain models (visceral pain, referred pain, incision pain)
- Neuralgia models (CCI, SNI)
- Respiratory disease models (asthma, COPD)
- Arthritis (CIA, AIA)
- Multiple sclerosis
- In vivo neutralization assay for TNF-α target drugs
- Graft-versus-host disease (GVHD)
Liver Diseases
- Alcoholic and non-alcoholic fatty liver disease
- Liver fibrosis
- Liver cirrhosis
- Ascites
Infectious Diseases
- Hepatitis B
- Viral infections (influenza)
- Bacterial infections
Metabolic Disease Models
- Obesity, type 1 and type 2 diabetes mellitus
- Liver fibrosis models (NAFLD & NASH)
- Kidney injury and chronic renal failure models
- Cardiovascular disease models (stroke, myocardial ischemia-reperfusion, hypertension)
Central Nervous System Disease Models
- Neurodegenerative disease models (Alzheimer’s disease, cognitive impairment, epilepsy, Parkinson’s disease)
- Rare disease models
In Vitro Pharmacology and Biomarker Detection
- Sample analysis includes: blood, cerebrospinal fluid, body fluids, urine, feces, and tissue extracts
- Gene and protein analysis: methods such as RT-PCR, ELISPOT, Auto MACS Pro, ELISA, Alpha LISA, WB, and MSD
- Flow cytometric analysis: tumor cells and immune cells
Histopathology Detection Platform
- Frozen sections
- Routine pathological staining
- Immunohistochemical staining
- Qualitative/quantitative analysis
Blood Detection Platform
- Blood biochemical analysis
- Blood cell analysis
- Others: skin pruritus, etc.
PD/PK
PD/PK experiments use normal or disease model animals to detect the distribution levels of test compounds and biomarkers in their circulatory system and different tissues, especially target organs, so as to determine the correlation between drug targets and drug metabolism levels.
Instruments and Equipment
- Flow cytometer
- ELISPOT
- Small animal in vivo imaging system